- Home
- PWR vs TAK Comparison
PWR vs TAK Comparison
Compare PWR & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWR
- TAK
- Stock Information
- Founded
- PWR 1997
- TAK 1781
- Country
- PWR United States
- TAK Japan
- Employees
- PWR N/A
- TAK N/A
- Industry
- PWR Engineering & Construction
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- PWR Industrials
- TAK Health Care
- Exchange
- PWR Nasdaq
- TAK Nasdaq
- Market Cap
- PWR 39.9B
- TAK 42.2B
- IPO Year
- PWR 1998
- TAK N/A
- Fundamental
- Price
- PWR $267.22
- TAK $14.71
- Analyst Decision
- PWR Strong Buy
- TAK
- Analyst Count
- PWR 20
- TAK 0
- Target Price
- PWR $317.61
- TAK N/A
- AVG Volume (30 Days)
- PWR 1.4M
- TAK 2.5M
- Earning Date
- PWR 05-01-2025
- TAK 05-08-2025
- Dividend Yield
- PWR 0.15%
- TAK 4.01%
- EPS Growth
- PWR 20.60
- TAK 15.39
- EPS
- PWR 6.03
- TAK 0.83
- Revenue
- PWR $23,672,795,000.00
- TAK $29,124,927,177.00
- Revenue This Year
- PWR $14.68
- TAK $8.53
- Revenue Next Year
- PWR $9.71
- TAK N/A
- P/E Ratio
- PWR $44.32
- TAK $34.69
- Revenue Growth
- PWR 13.36
- TAK 9.83
- 52 Week Low
- PWR $227.08
- TAK $12.58
- 52 Week High
- PWR $365.88
- TAK $15.37
- Technical
- Relative Strength Index (RSI)
- PWR 51.97
- TAK 52.69
- Support Level
- PWR $227.08
- TAK $13.60
- Resistance Level
- PWR $277.70
- TAK $15.37
- Average True Range (ATR)
- PWR 13.21
- TAK 0.33
- MACD
- PWR 2.43
- TAK -0.03
- Stochastic Oscillator
- PWR 79.30
- TAK 62.71
About PWR Quanta Services Inc.
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric infrastructure and underground utility and infrastructure.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.